[Heparin-induced thrombocytopenia]

Area of Science:

• Hematology
• Pharmacology
• Clinical Medicine

Background:

• Heparin is a widely used anticoagulant for preventing and treating blood clots.
• While generally safe, heparin can paradoxically cause a dangerous condition known as heparin-induced thrombocytopenia (HIT).

Purpose of the Study:

• To review the pathogenesis, clinical features, diagnosis, and management of heparin-induced thrombocytopenia.
• To discuss the prognosis and prophylaxis of this potentially life-threatening disorder.

Main Methods:

• This review synthesizes information on heparin-induced thrombocytopenia from existing literature.
• Key aspects covered include different types of HIT, diagnostic methods, and therapeutic strategies.

Main Results:

• Heparin-induced thrombocytopenia presents in two forms: nonimmune (common, mild) and immune-mediated (rare, severe).
• Immune-mediated HIT, despite causing severe thrombocytopenia, paradoxically elevates the risk of arterial and venous thrombosis.

Conclusions:

• Heparin-induced thrombocytopenia is a critical complication of heparin therapy requiring careful management.
• Early diagnosis and appropriate treatment, including direct thrombin inhibitors, are crucial for managing HIT and preventing thrombotic events.